Clear Cell Carcinoma Of The Ovary: An Experience From A Regional Cancer Centre In Odisha.

Background: Clear cell carcinoma of the ovary (CCCO) shows unique clinical features. There is a remarkable difference in incidence among different ethnic populations. The reasons for these differences in incidence around the world are not known. Aim and objectives: To evaluate the clinical characteristics of patients with CCCO and to determine the impact of the stage of the disease and the extent of surgery on the prognosis of those patients. Materials and methods: A retrospective analysis of the cases of clear cell carcinoma of the ovary that were operated in the regional cancer centre, Cuttack, from January 2009 to December 2018, was performed to evaluate the clinical characteristics and prognostic factors of the patients. Results: During this study period, the incidence of CCCO was found to be 1.92%. The most common age group was 40–50 years (mean age of 44.7 years). The most common modes of presentation were abdominal distention and pain in the abdomen. Most of the cases in this study belonged to stage III C (65%), making it the most common stage in this group. 20% of the patients within the study group were nulliparous and 35% were menopausal in status.40% of the tumours were >15 cm in size. Almost 28% were lymph node positive. None in stage I had positive lymph nodes. All the cases in stage III were positive for lymph nodes. So, in stage III, 38.5% were positive for lymph nodes. 17/20 had some form of chemotherapy, of which 45% had NACT. Survival curves differ significantly between the early and advanced stages of the disease. A trend of survival benefit is seen with complete cytoreduction. Conclusion: There is a need for data regarding the incidence and specific clinicopathologic behaviour of clear cell carcinoma of the ovary in the Indian population. This is an attempt to compile the data from a single tertiary institute in eastern India over the past 10 years. This is a rare tumour and the chances of missing data are well accepted. The survival advantage of early-stage-diagnosed patients over late-stage patients is tremendous and hard to ignore. Combining the fact that clear cell carcinomas are associated with precancerous lesions like atypical endometriosis and atypical adenofibroma, there may be scope for screening. The mutational changes leading to malignancy in these precancerous lesions also need to be refined. As stated, complete cytoreduction is the key to survival advantage and the need for referral to a centre with proper expertise for the same needs to be emphasized.

An Observational Study of Peripherally Inserted Central Cather(PICC)-Related Complications Amongst Oncology Patients

<p>This thesis reports on a retrospective observational study that examined the complication rate of peripherally inserted central catheters (PICCs) within a regional cancer centre. PICCs are increasingly used for delivery of chemotherapy and other intravenous therapies in oncology patients. A literature review revealed that almost all published research on PICC complications reported on silicone (Groshong(TM)) catheter use, rather than the polyurethane (Arrow(TM)) PICCs used at Christchurch Hospital. Also, much literature referred to PICCs being inserted by non-nurses, whereas the Christchurch service uses specially-trained nurses to insert them. The purpose of the study was to identify the nature, incidence and rates of polyurethane (Arrow(TM)) PICC complications in an adult oncology cohort. Ethics Committee approval was gained to retrospectively follow all PICCs inserted in adult oncology patients at Christchurch Hospital over a 13-month period from 1st March 2006 until 31st March 2007. Data collected were analysed utilising the statistical computer package SPSS. One hundred and sixty-four PICCs were inserted into 156 individual oncology patients over this period. The median dwell time was 68 days (range 6-412, IQR 39-126) for a total of 14,276 catheter-days. Complications occurred in 25 (15%) out of 164 PICC lines, in 22 (15%) of the 156 patients for an overall complication rate of 1.75 per 1000 catheter-days. However, only 16 of the 25 PICCs with complications required early removal (9.75% of the cohort) for a favourably low serious complication rate of 1.12 per 1000 catheter-days. The three commonest complications were infection at 4.3% (7/164) or 0.49 infection complications/1000 PICC-days, PICC migration at 3% (5/164) or 0.35/1000 catheter days, and thrombosis at 2.4% (4/164) or 0.28/1000 catheter days. The median time to complication was 41 days (range 2-160, IQR 25-77). Those with complications were more likely to have a gastro-intestinal or an ovarian cancer diagnosis, and less likely to have colorectal cancer (p=0.001). These findings provide support for the safe and effective use of polyurethane (Arrow(TM)) PICCs for venous access within the adult oncology context. Furthermore, it suggests that cost effective nurse-led (Arrow(TM)) PICC insertions can contribute to a low complication rate. This benchmark study should be followed by further prospective studies examining the relationship of cancer diagnosis to PICC complication rates in oncology patients.</p>

An Observational Study of Peripherally Inserted Central Cather(PICC)-Related Complications Amongst Oncology Patients

<p>This thesis reports on a retrospective observational study that examined the complication rate of peripherally inserted central catheters (PICCs) within a regional cancer centre. PICCs are increasingly used for delivery of chemotherapy and other intravenous therapies in oncology patients. A literature review revealed that almost all published research on PICC complications reported on silicone (Groshong(TM)) catheter use, rather than the polyurethane (Arrow(TM)) PICCs used at Christchurch Hospital. Also, much literature referred to PICCs being inserted by non-nurses, whereas the Christchurch service uses specially-trained nurses to insert them. The purpose of the study was to identify the nature, incidence and rates of polyurethane (Arrow(TM)) PICC complications in an adult oncology cohort. Ethics Committee approval was gained to retrospectively follow all PICCs inserted in adult oncology patients at Christchurch Hospital over a 13-month period from 1st March 2006 until 31st March 2007. Data collected were analysed utilising the statistical computer package SPSS. One hundred and sixty-four PICCs were inserted into 156 individual oncology patients over this period. The median dwell time was 68 days (range 6-412, IQR 39-126) for a total of 14,276 catheter-days. Complications occurred in 25 (15%) out of 164 PICC lines, in 22 (15%) of the 156 patients for an overall complication rate of 1.75 per 1000 catheter-days. However, only 16 of the 25 PICCs with complications required early removal (9.75% of the cohort) for a favourably low serious complication rate of 1.12 per 1000 catheter-days. The three commonest complications were infection at 4.3% (7/164) or 0.49 infection complications/1000 PICC-days, PICC migration at 3% (5/164) or 0.35/1000 catheter days, and thrombosis at 2.4% (4/164) or 0.28/1000 catheter days. The median time to complication was 41 days (range 2-160, IQR 25-77). Those with complications were more likely to have a gastro-intestinal or an ovarian cancer diagnosis, and less likely to have colorectal cancer (p=0.001). These findings provide support for the safe and effective use of polyurethane (Arrow(TM)) PICCs for venous access within the adult oncology context. Furthermore, it suggests that cost effective nurse-led (Arrow(TM)) PICC insertions can contribute to a low complication rate. This benchmark study should be followed by further prospective studies examining the relationship of cancer diagnosis to PICC complication rates in oncology patients.</p>

Oncology patients’ experiences in experimental medicine cancer trials: a qualitative study

ObjectivesThe study aimed to explore patients’ experiences of experimental cancer medicine (ECM) clinical trials.DesignThe study’s design was qualitative. Two focus groups with patients were undertaken followed by semistructured interviews, to explore patients’ experiences of ECM clinical trials. Interviews and focus groups were audiorecorded and transcribed verbatim. Data were analysed using thematic analysis.SettingA regional cancer centre (tertiary care) in North-West England.ParticipantsTwelve patients (aged 52–79) participated in one of the two focus groups and 22 patients (aged 42–83) participated in interviews.Primary outcome measurePatients’ experiences of an ECM trial.ResultsFour main themes were identified from the analysis: decision making, information needs, the experience of trial participation and impact of trial participation. Subthemes are presented in the manuscript.ConclusionTo make fully informed decisions about trial participation, patients required the simplification of trial information and wanted more information about side effects, their response to trial treatment and the overall trial progress throughout the trial. Patients highlighted the need for improvement for the support provided to their family and friends.

Patient involvement at the managerial level: the effectiveness of a patient and family advisory council at a regional cancer centre in Sweden

Background In cancer care as well as other types of treatment and care, little is known about the contribution of Patient and Family Advisory Councils (PFACs) operating at the managerial level in healthcare organizations. The aim of the study was to investigate the effectiveness of a Swedish PFAC operating at the managerial level at one of Sweden’s six regional cancer centres. Methods This was a qualitative, single-case study based on interviews with PFAC participants and meeting minutes from PFAC meetings. These were analysed using a modified version of a framework developed by Abelson et al. to design and evaluate collective involvement processes in the healthcare sector: (i) representation; (ii) information; (iii) process or procedures and (iv) outcomes and decisions. Results The descriptive representation was good regarding geographical location and cancer diagnosis. Information from the regional cancer centre was an important part of the meeting agenda. The procedures encouraged everyone to speak up, and the participants saw the representatives from the regional cancer centre as allies against the hospitals and regions, raising some questions about the PFAC's independence. Regarding outcomes, most participants did not know to what extent their work had led to any improvements in cancer care. However, they still regarded the council as effective, as issues the participants raised were listened to by the representatives from the regional cancer centre and ‘taken further’ in the healthcare organization. Conclusions The participants were satisfied with being listened to, but they found it difficult to know whether their work had led to improvements, in part because they did not know enough about how the healthcare organization worked above the care-provision level. This was a hurdle to achieving change. The study suggests it is more difficult for patients and next of kin to participate at the managerial level, compared to the care-provision level in healthcare systems, where they could potentially influence important aspects of cancer care and policy, since it is at these levels strategic decisions about priorities in cancer care and service configurations are made. This indicates that there is a particular need for guidance and support for patient and public involvement to work successfully at this level, which may include relevant education and training in system knowledge.